DPP-4 inhibition by Saxagilptin prevents inflammation and renal injury by targeting the Nirp3/ASC inflammasome

Project: Other project

StatusFinished
Effective start/end date10/1/1412/12/17

Funding

  • AstraZeneca LP: $101,947.76